As an Impact Fund:  to hold ourselves and HIC ‘s portfolio companies to a hig

Authored by HIC Venture Fellows

press to zoom
Fireside Chat Series
Fireside Chat Series

Coming soon in collaboration with leading experts in pediatrics.

press to zoom

Authored by HIC Venture Fellows

press to zoom
1/2

THOUGHT LEADERSHIP

HIC team members are thought leaders at the intersection of healthcare innovation, pediatrics and venture capital. 

iStock-462586235.jpg

Characterizing the tumor microenvironment in rare renal cancer histological types

VF: Naoise Synnott

iStock-462586235.jpg

Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint

VF: Reilly Dever

iStock-462586235.jpg

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

VF: Naoise Synnott

iStock-462586235.jpg

The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression

VF: Esmeralda Ramirez-Peña 

iStock-462586235.jpg

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

VF: Naoise Synnott

iStock-462586235.jpg

Distinguishing mechanisms underlying
EMT tristability

VF: Esmeralda Ramirez-Peña